Lupus nephritis (LN) is an immune complex-mediated glomerulonephritis. Proliferative LN (PLN, ISN/RPS classes III and IV)) often leads to renal injury or failure despite traditional induction and maintenance therapy. Successful targeted therapeutic development requires insight into mediators of inflammation in PLN. Superoxide (SO) and its metabolites are mediators of the innate immune response through their ability to mediate reduction–oxidation signaling. Endothelial nitric oxide synthase (eNOS) modulates inflammatory responses in endothelial cells. We hypothesized that markers of SO production would be increased in active PLN and that SO production would be dependent on the activity of select enzymes in the renal cortex.
Methods
Patients with systemic lupus erythematosus were enrolled at the time of renal biopsy for active LN of all classes. Serum collected at baseline was analyzed by HPLC with electrochemical detection for markers of SO production (durable modifications of serum protein Tyr ultimately requiring SO as a substrate). Renal cortex from MRL/MpJ-FASlpr (MRL/lpr) mice with and without functional eNOS was analyzed during active disease for superoxide (SO) production with and without inhibitors of SO-producing enzymes.
Results
Serum protein modifications indicative of total SO production were significantly higher in patients with PLN. These markers were increased in association with more active, inflammatory PLN. Mice lacking functional eNOS had 80% higher levels of renal cortical SO during active disease, and inhibitors of nitric oxide synthase and NADPH oxidase reduced these levels by 60% and 77%, respectively.
Conclusion
These studies demonstrate that SO production is unique to active PLN in a NOS and NADPH oxidase-dependent fashion. These findings suggest the emulating or augmenting eNOS activity or inhibiting NADPH oxidase SO production may be targets of therapy in patients with PLN. The markers of SO production used in this study could rationally be used to select SO-modulating therapies and serve as pharmacodynamic indicators for dose titration.
WeeningJJD'AgatiVDSchwartzMM. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int2004; 65: 521–530.
2.
DooleyMAHoganSJennetteCFalkR. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int1997; 51: 1188–1195.
3.
OatesJCChristensenEFReillyCMSelfSEGilkesonGS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: Correlation with disease activity. Proc Assoc Am Phys1999; 111: 611–621.
4.
FurusuAMiyazakiMAbeK. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int1998; 53: 1760–1768.
5.
OatesJCShaftmanSRSelfSEGilkesonGS. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum2008; 58: 263–272.
6.
NjokuCSelfSERuizPHofbauerAFGilkesonGSOatesJC. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. J Investig Med2008; 56: 911–919.
7.
GilkesonGSMudgettJSSeldinMF. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J Exp Med1997; 186: 365–373.
Janssen-HeiningerYMMossmanBTHeintzNH. Redox-based regulation of signal transduction: Principles, pitfalls, and promises. Free Radic Biol Med2008; 45: 1–17.
10.
FiebelerAParkJKMullerDN. Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. Am J Kidney Dis2004; 43: 286–295.
11.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
12.
AustinHA3rd, MuenzLRJoyceKM. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med1983; 75: 382–391.
13.
AustinHA3rd, MuenzLRJoyceKMAntonovychTTBalowJE. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int1984; 25: 689–695.
14.
HensleyKWilliamsonKSFloydRA. Measurement of 3-nitrotyrosine and 5-nitro-gamma-tocopherol by high-performance liquid chromatography with electrochemical detection. Free Radic Biol Med2000; 28: 520–528.
15.
CrowleyJRYarasheskiKLeeuwenburghCTurkJHeineckeJW. Isotope dilution mass spectrometric quantification of 3-nitrotyrosine in proteins and tissues is facilitated by reduction to 3-aminotyrosine. Anal Biochem1998; 259: 127–135.
16.
VyseTJToddJA. Genetic analysis of autoimmune disease. Cell1996; 85: 311–318.
17.
VidalSKonoDHTheofilopoulosAN. Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice. J Clin Invest1998; 101: 696–702.
18.
WatsonMLRaoJKGilkesonGS. Genetic analysis of MRL-lpr mice: Relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med1992; 176: 1645–1656.
19.
GilkesonGSMashmoushiAKRuizPCazaTNPerlAOatesJC. Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis. PLoS ONE2013; 8: e64650–e64650.
20.
HagiwaraMBledsoeGYangZRSmithRSJr., ChaoLChaoJ. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol2008; 295: F1735–F1743.
21.
GupteSALevineRJGupteRS. Glucose-6-phosphate dehydrogenase-derived NADPH fuels superoxide production in the failing heart. J Mol Cell Cardiol2006; 41: 340–349.
22.
GilkesonGSMashmoushiAKRuizPCazaTNPerlAOatesJC. Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis. PloS One2013; 8: e64650–e64650.
23.
MoroniGNovembrinoCQuagliniS. Oxidative stress and homocysteine metabolism in patients with lupus nephritis. Lupus2010; 19: 65–72.
24.
NishikawaMIgarashiRNakazawaTAikawaE. Rescue of (NZB × NZW) F1 mice from oxygen-derived free radical injury by use of phosphatidylcholine-modified superoxide dismutase. Lab Anim Sci1999; 49: 560–564.
25.
SuwannarojSLagooAKeislerDMcMurrayRW. Antioxidants suppress mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus2001; 10: 258–265.
26.
CookeMSMistryNWoodCHerbertKELunecJ. Immunogenicity of DNA damaged by reactive oxygen species – implications for anti-DNA antibodies in lupus. Free Radic Biol Med1997; 22: 151–159.
27.
GriffithsHR. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease?Autoimmun Rev2008; 7: 544–549.
28.
WeinbergJBGrangerDLPisetskyDS. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L- arginine. J Exp Med1994; 179: 651–660.
29.
PoberJSSessaWC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol2007; 7: 803–815.
30.
ShahDWanchuABhatnagarA. Interaction between oxidative stress and chemokines: Possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology2011; 216: 1010–1017.
31.
KabeYAndoKHiraoSYoshidaMHandaH. Redox regulation of NF-kappaB activation: Distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal2005; 7: 395–403.
32.
BrunnerHIBennettMRMinaR. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum2012; 64: 2687–2697.
33.
LiYTucciMNarainS. Urinary biomarkers in lupus nephritis. Autoimmun Rev2006; 5: 383–388.
VolkTHenselMSchusterHKoxWJ. Secretion of MCP-1 and IL-6 by cytokine stimulated production of reactive oxygen species in endothelial cells. Mol Cell Biochem2000; 206: 105–112.
40.
BendallJKAlpNJWarrickN. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: Insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res2005; 97: 864–871.
41.
LandmesserUDikalovSPriceSR. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest2003; 111: 1201–1209.
42.
BedardKKrauseKH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev2007; 87: 245–313.
43.
PricopLGokhaleJRedechaPNgSCSalmonJE. Reactive oxygen intermediates enhance Fc gamma receptor signaling and amplify phagocytic capacity. J Immunol1999; 162: 7041–7048.
44.
SumiyoshiKMokunoHIesakiT. Deletion of the Fc receptors gamma chain preserves endothelial function affected by hypercholesterolaemia in mice fed on a high-fat diet. Cardiovasc Res2008; 80: 463–470.
45.
StielowCCatarRAMullerG. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun2006; 344: 200–205.
46.
SelemidisSDustingGJPeshavariyaHKemp-HarperBKDrummondGR. Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc Res2007; 75: 349–358.
47.
PleskovaMBeckKFBehrensMH. Nitric oxide down-regulates the expression of the catalytic NADPH oxidase subunit Nox1 in rat renal mesangial cells. FASEB J2006; 20: 139–141.
48.
KissESolteszPDerH. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun2006; 27: 211–217.
